Literature DB >> 30576008

Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism.

Michela Barichella1, Marco Severgnini2, Roberto Cilia1, Erica Cassani1, Carlotta Bolliri1, Serena Caronni1, Valentina Ferri1, Raffaella Cancello3, Camilla Ceccarani2,4, Samanta Faierman1, Giovanna Pinelli1,5, Gianluca De Bellis2, Luigi Zecca2,6, Emanuele Cereda7, Clarissa Consolandi2, Gianni Pezzoli1.   

Abstract

BACKGROUND: Although several studies have suggested that abnormalities in gut microbiota may play a critical role in the pathogenesis of PD, data are still extremely heterogeneous.
METHODS: 16S gene ribosomal RNA sequencing was performed on fecal samples of 350 individuals, subdivided into idiopathic PD (n = 193, of whom 39 were drug naïve) stratified by disease duration, PSP (n = 22), MSA (n = 22), and healthy controls (HC; n = 113). Several confounders were taken into account, including dietary habits.
RESULTS: Despite the fact that unadjusted comparison of PD and HC showed several differences in relative taxa abundances, the significant results were greatly reduced after adjusting for confounders. Although most of these differences were associated with disease duration, lower abundance in Lachnospiraceae was the only difference between de novo PD and HC (remaining lower across almost all PD duration strata). Decreased Lachnospiraceae and increased Lactobacillaceae and Christensenellaceae were associated with a worse clinical profile, including higher frequencies of cognitive impairment, gait disturbances, and postural instability. When compared with HC, MSA and PSP patients shared the changes in PD, with a few exceptions: in MSA, Lachnospiraceae were not lower, and Prevotellaceae were reduced; in PSP, Lactobacillaceae were similar, and Streptococcaceae were reduced.
CONCLUSIONS: Gut microbiota may be an environmental modulator of the pathogenesis of PD and contribute to the interindividual variability of clinical features. Data are influenced by PD duration and several confounders that need to be taken into account in future studies. Prospective studies in de novo PD patients are needed to elucidate the net effect of dysbiosis on the progression of the disease.
© 2018 International Parkinson and Movement Disorder Society. © 2018 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  MSA; PD; PSP; Parkinson-s disease; clinical features; gut-brain axis; multiple system atrophy; progressive supranuclear palsy

Year:  2018        PMID: 30576008     DOI: 10.1002/mds.27581

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  65 in total

1.  Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.

Authors:  Zachary D Wallen; Mary Appah; Marissa N Dean; Cheryl L Sesler; Stewart A Factor; Eric Molho; Cyrus P Zabetian; David G Standaert; Haydeh Payami
Journal:  NPJ Parkinsons Dis       Date:  2020-06-12

Review 2.  The gut microbiota-brain axis in behaviour and brain disorders.

Authors:  Livia H Morais; Henry L Schreiber; Sarkis K Mazmanian
Journal:  Nat Rev Microbiol       Date:  2020-10-22       Impact factor: 60.633

3.  Genome-wide screen identifies curli amyloid fibril as a bacterial component promoting host neurodegeneration.

Authors:  Chenyin Wang; Chun Yin Lau; Fuqiang Ma; Chaogu Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-24       Impact factor: 11.205

Review 4.  The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic.

Authors:  Ai Huey Tan; Shen Yang Lim; Anthony E Lang
Journal:  Nat Rev Neurol       Date:  2022-06-24       Impact factor: 44.711

Review 5.  Central and Peripheral Inflammation: Connecting the Immune Responses of Parkinson's Disease.

Authors:  Gregory P Williams; Aubrey M Schonhoff; Alessandro Sette; Cecilia S Lindestam Arlehamn
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 6.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

Review 7.  Gut Vibes in Parkinson's Disease: The Microbiota-Gut-Brain Axis.

Authors:  Clara Bullich; Ali Keshavarzian; Johan Garssen; Aletta Kraneveld; Paula Perez-Pardo
Journal:  Mov Disord Clin Pract       Date:  2019-10-23

Review 8.  The Gut-Brain Axis: Two Ways Signaling in Parkinson's Disease.

Authors:  Nitu Dogra; Ruchi Jakhmola Mani; Deepshikha Pande Katare
Journal:  Cell Mol Neurobiol       Date:  2021-03-02       Impact factor: 5.046

9.  The impact of device-assisted therapies on the gut microbiome in Parkinson's disease.

Authors:  Michal Lubomski; Xiangnan Xu; Jean Y H Yang; Carolyn M Sue; Ryan L Davis; Andrew J Holmes
Journal:  J Neurol       Date:  2021-06-15       Impact factor: 6.682

10.  Identification of amyloidogenic proteins in the microbiomes of a rat Parkinson's disease model and wild-type rats.

Authors:  Line Friis Bakmann Christensen; Saeid Hadi Alijanvand; Michał Burdukiewicz; Florian-Alexander Herbst; Henrik Kjeldal; Morten Simonsen Dueholm; Daniel E Otzen
Journal:  Protein Sci       Date:  2021-06-09       Impact factor: 6.993

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.